David M. Margolis

This study identifies an HIV-1 Tat variant (R52W) that reduces transcriptional activity, potentially contributing to viral persistence during ART.

In ART-suppressed human brain, an SPP1+ activated microglial subset holds most detected HIV RNA and shows chronic interferon-I and MHC-I signatures, alongside complement signaling and neuronal loss.

This study identifies chromatin regulators of HIV latency and reactivation using RelB proximity proteomics and CRISPR screening, revealing key acetyltransferases involved in noncanonical NF-κB pathway activation.

The paper analyzes HIV integration sites and expression in CD4 T cells, finding no significant variation in viral expression based on integration site features but identifying insertional activation of host genes in some cells.

The paper identifies TAF1 as a novel regulator of HIV latency through a chemical screen and genetic experiments, showing its role in maintaining viral transcriptional silence.

This paper identifies the ENL-USP7 complex as a host factor that stabilizes BRD4 to maintain HIV-1 latency and shows that disrupting this complex reactivates latent HIV.

This study investigates how THC affects HIV-infected CD4 T cells using single-cell multiomic analysis, finding no effect on HIV reactivation but altered gene expression and chromatin accessibility.

This study identifies Vpr's transcription-promoting activity in HIV-1 latency, showing it is inhibited by HDACs and contributes to reservoir formation in CD4+ T cells.

This paper identifies ETS1 as a regulator of HIV latency through a CRISPR screen and shows it has opposing roles in actively and latently infected CD4 T cells.

This study shows that BRD4 degraders are less effective than BET inhibitors in reactivating latent HIV in CD4+ T-cells, highlighting the importance of BRD4's role in disrupting 7SK and P-TEFb.

This study identifies transcriptomic clusters in HIV patients on ART linked to immune recovery and inflammation markers, revealing novel subgroups with distinct immunological profiles.

The paper identifies HDAC inhibitors as agents that prevent HIV latency by maintaining viral expression and altering memory T cell phenotypes in infected cells.

The paper identifies a microglia-specific promoter of the human HexB gene that can be used for AAV gene therapy targeting microglia in the CNS.

The paper demonstrates that AZD5582, a SMACm mimic, effectively reverses HIV latency in patient-derived cells without significant off-target effects.